CRISPR Therapeutics (NASDAQ:CRSP) Stock Backdrop Is Even More Problematic In The Post-Covid Era!

With the outburst of the corona virus pandemic, the economy of the world has been shaken with various sectors hit hard. Even the most relevant sectors such as Biotechnology is no exception. Hopefully, situations would get better soon and things would work in favour of companies like CRISPR Therapeutics (NASDAQ:CRSP) who might contribute their share in resolving chronic issues.

CRISPR Therapeutics is focused on the development of transformative medicines using its proprietary CRISPR/Cas9 gene-editing platform. As the name itself implies the firm specializes in CRISPR (Clustered Regularly Interspaced Short Palindromic Repeat) technology which is an innovation that allows “researchers to easily alter DNA sequences and modify gene function.” Among the many applications the company’s most advanced product is CTX001 whose main aim is to treat sickle-cell anemia. The company is also engaged in extensive research in order to provide treatments for Duchenne muscular dystrophy and cystic fibrosis as well.

Taking into consideration that these are all diseases with significant human tolls and often high mortality rates, the company would be a huge success provided its broader gene editing technology works. Anticipations reveals that there is a huge possibility of the same to work to at least some degree against all of these diseases. However, this could be a big gamble for the company as one cannot overlook the risk factors as the gene therapy, till date has not proven to be cost-effective, which may end up biting CRSP stock in the rear.

Also, the chances of the company providing an effective therapy is also not cent percent. Even if the company manages to produce an effective therapy, it must make sure that it’s safe and won’t cause other problems down the line. Also, one major question that tickles is whether the therapy would be accessible to the masses or would it be able to fulfill the requirements of the riches.